BOSTON & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tahoe Therapeutics and Alloy Therapeutics announced today that they are forming a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for patients with hard-to-treat cancers.

Read more here.